Resources Management Corp CT ADV purchased a new position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 2,489 shares of the biopharmaceutical company’s stock, valued at approximately $244,000.
A number of other institutional investors have also bought and sold shares of ALXN. Signaturefd LLC boosted its position in Alexion Pharmaceuticals by 13.2% during the second quarter. Signaturefd LLC now owns 822 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 96 shares during the period. Investors Research Corp lifted its stake in shares of Alexion Pharmaceuticals by 52.0% during the 3rd quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 104 shares during the last quarter. Synovus Financial Corp boosted its holdings in shares of Alexion Pharmaceuticals by 4.6% during the 3rd quarter. Synovus Financial Corp now owns 2,391 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 106 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Alexion Pharmaceuticals by 6.5% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,810 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 111 shares during the period. Finally, Verity Asset Management Inc. boosted its holdings in shares of Alexion Pharmaceuticals by 4.1% during the 2nd quarter. Verity Asset Management Inc. now owns 2,842 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 112 shares during the period. Institutional investors and hedge funds own 91.60% of the company’s stock.
Shares of NASDAQ:ALXN opened at $115.45 on Friday. The company’s 50 day moving average price is $108.21 and its two-hundred day moving average price is $112.90. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $141.86. The firm has a market cap of $25.21 billion, a PE ratio of 16.28, a PEG ratio of 1.08 and a beta of 1.67. The company has a quick ratio of 3.45, a current ratio of 3.98 and a debt-to-equity ratio of 0.25.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.32. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.02 earnings per share. On average, research analysts expect that Alexion Pharmaceuticals, Inc. will post 9.43 EPS for the current year.
Several research analysts have weighed in on the stock. Citigroup set a $150.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. Bank of America initiated coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, October 17th. They set a “buy” rating for the company. Credit Suisse Group reduced their price objective on Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Stifel Nicolaus reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Friday, August 30th. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $156.37.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
See Also: What is a stock portfolio tracker?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.